A1LN34 Aktienübersicht Alnylam Pharmaceuticals, Inc. erforscht, entwickelt und vermarktet Therapeutika, die auf der Interferenz von Ribonukleinsäuren basieren. Mehr Details
Belohnungen Risikoanalyse Bei unseren Risikoprüfungen wurden keine Risiken für A1LN34 festgestellt.
Alle Risikoprüfungen anzeigen Community vs My Fair Value Select a narrative for quick price alerts from the community, or create your own.
Alnylam Pharmaceuticals, Inc. Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Alnylam Pharmaceuticals Historische Aktienkurse Aktueller Aktienkurs US$79.66 52-Wochen-Hoch US$85.44 52-Wochen-Tief US$36.84 Beta 0.39 1 Monat Veränderung -1.37% 3 Monate Veränderung 7.87% 1 Jahr Veränderung 119.87% 3 Jahre Veränderung 106.05% 5 Jahre Veränderung n/a Veränderung seit IPO 95.97%
Aktuelle Nachrichten und Updates
Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 08, 2025 Mar 18
Alnylam Pharmaceuticals, Inc. Announces Retirement of Phillip A. Sharp from the Board of Directors, Effective May 8, 2025 Mar 06
Alnylam Highlights Significant Pipeline Progress and Platform Innovation At R&D Day Feb 26
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2025 Feb 14
Alnylam Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 13, 2025 Jan 30
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year 2025 Jan 13 Weitere Updates anzeigen
Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 08, 2025 Mar 18
Alnylam Pharmaceuticals, Inc. Announces Retirement of Phillip A. Sharp from the Board of Directors, Effective May 8, 2025 Mar 06
Alnylam Highlights Significant Pipeline Progress and Platform Innovation At R&D Day Feb 26
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2025 Feb 14
Alnylam Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 13, 2025 Jan 30
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year 2025 Jan 13
Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Nov 25
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 Nov 01
Alnylam Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 17
Alnylam Pharmaceuticals, Inc. Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy Oct 16
Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy Oct 09
Alnylam Highlights New Data from Helios-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 Oct 01
Alnylam Pharmaceuticals, Inc. Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress Aug 30
Alnylam Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2024 Aug 02
Alnylam Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 18
Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations Jun 24
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024 May 03
Alnylam Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024 Apr 20
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension Apr 09
Alnylam Pharmaceuticals, Inc., Annual General Meeting, May 16, 2024 Mar 20
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives Mar 05
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for Full Year Ending December 31, 2024 Feb 15
Alnylam Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024 Jan 30
Alnylam Pharmaceuticals, Inc. Announces Transition of Indrani L. Franchini as Executive Vice President, Chief Legal Officer and Secretary, Effective on March 1, 2024 Jan 20
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk Nov 12 Alnylam Pharmaceuticals, Inc. Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Alnylam Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Oct 20
Alnylam Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Oct 11
Marsha H. Fanucci Resigns from Board of Directors of Alnylam Pharmaceuticals, Inc Sep 29 Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran Sep 08
Alnylam Pharmaceuticals, Inc. Announces Management Changes, Effective October 2, 2023
Alnylam Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 23
Alnylam Pharmaceuticals, Inc. Reports Updated Positive Interim Phase 1 Results for ALN-App, in Development for Alzheimer's Disease and Cerebral Amyloid Angiopathy Jul 18
Alnylam Pharmaceuticals, Inc. Presents 18-Month Results from the Apollo-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy May 21
Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year of 2023 May 05
Alnylam Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 03
Alnylam Pharmaceuticals, Inc. Announces Board Changes Jan 06
Alnylam Pharmaceuticals, Inc. Submits CTA Application for Aln-Khk, an Investigational RNAi therapeutic for the Treatment of Type 2 Diabetes Dec 22
Alnylam Pharmaceuticals, Inc. Submits Supplemental New Drug Application to U.S. Food and Drug Administration for ONPATTRO® (Patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis Dec 09
Alnylam Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022 Oct 28
Alnylam Pharmaceuticals, Inc. to Report Q3, 2022 Results on Oct 27, 2022 Oct 14
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1 Oct 07
Alnylam Pharmaceuticals, Inc. Presents Additional Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy At Heart Failure Society of America Annual Meeting Oct 01
Alnylam Pharmaceuticals, Inc. Announces Executive Appointments Sep 22
Alnylam Pharmaceuticals, Inc. Receives Approval in Europe for AMVUTTRA (Vutrisiran) for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy Sep 21 Alnylam Pharmaceuticals, Inc. and Regeneron Pharmaceuticals Announces Preliminary Phase 1 Data Supporting the Clinical Advancement of ALN-HSD Alnylam Presents Positive Results from the Apollo-B Phase 3 Study of Patisiran in Patients with Attr Amyloidosis with Cardiomyopathy Sep 08
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy Aug 30
Alnylam Appoints Elliott Sigal, M.D., Ph.D., to Board of Directors Aug 25
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Aug 04
Alnylam Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Vutrisiran for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy Jul 23
Alnylam Pharmaceuticals, Inc. to Report Q2, 2022 Results on Jul 28, 2022 Jul 19
Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults Jun 14
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of Iga Nephropathy Jun 10
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering Rna to the Central Nervous System and Other Extrahepatic Tissues Jun 03
Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 May 26
Alnylam Pharmaceuticals, Inc. Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1 May 25
Alnylam Pharmaceuticals, Inc. Announces New Positive Results from an 18-Month Analysis of Exploratory Cardiac Endpoints in the HELIOS-A Phase 3 Study of Vutrisiran May 24
Alnylam Pharmaceuticals, Inc. Announces That Health Canada Has Issued A Notice of Compliance (Noc) Authorizing Oxlumo™ (Lumasiran) Injection for Subcutaneous Use for the Treatment May 19
Alnylam Pharmaceuticals, Inc. to Report Q1, 2022 Results on Apr 28, 2022 Apr 15 Alnylam Pharmaceuticals, Inc. Announces Retirement of Steven Paul from Board of Directors
Alnylam Pharmaceuticals, Inc. Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran Apr 05
Alnylam Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for OXLUMO® for the Treatment of Advanced Primary Hyperoxaluria Type 1 Mar 03
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022 Feb 11
Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy Jan 22
Alnylam Pharmaceuticals, Inc. to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting Jan 16 Alnylam Comments on FDA Approval of Leqvio, the First Sirna (Rnai Therapeutic) Approved to Reduce LDL-C Alnylam Pharmaceuticals, Inc. Initiates Phase 2 Study of Lumasiran in Patients with Recurrent Kidney Stone Disease
Alnylam Pharmaceuticals, Inc. Submits Regulatory Applications to the U.S. Food and Drug Administration and European Medicines Agency to Support Label Expansion for Oxlumo® for the Treatment of Advanced Primary Hyperoxaluria Type 1 Dec 15
Alnylam Pharmaceuticals, Inc. Submits Marketing Authorization Application to European Medicines Agency for Investigational Vutrisiran for Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy Sep 14 Alnylam Pharmaceuticals, Inc. Presents Additional 9-Month Data from Helios-A Phase 3 Study of Vutrisiran at the European ATTR Amyloidosis Meeting
Alnylam Pharmaceuticals, Inc. Completes Enrollment in HELIOS-B Phase 3 Study of Investigational Vutrisiran in Patients with Transthyretin-Mediated (ATTR) Amyloidosis with Cardiomyopathy Aug 10
Alnylam Pharmaceuticals, Inc. Updates Revenue Guidance for the Full Year of 2021 Aug 05
Alnylam Pharmaceuticals, Inc. Initiates KARDIA-1 Phase 2 Study of Zilebesiran (ALN-AGT) in Patients with Mild-to-Moderate Hypertension Jul 01
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis Jun 25
Alnylam Pharmaceuticals, Inc. Announces New Data from ATTR Amyloidosis Programs at the Peripheral Nerve Society’s 2021 Annual Meeting Jun 08
Alnylam Pharmaceuticals, Inc. Completes Enrollment in APOLLO-B Phase 3 Study of Patisiran in Transthyretin-Mediated (ATTR) Amyloidosis Patients with Cardiomyopathy Jun 02
Alnylam Pharmaceuticals, Inc. Announces New Advances in ATTR Amyloidosis Program May 12
Alnylam Pharmaceuticals, Inc. Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran) May 04
Alnylam Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2021 Apr 30
Alnylam Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 11, 2021 Jan 29
Alnylam Launches “Alnylam P5x25” Strategy for Planned Transition to Top Five Biotech in Market Capitalization over Next Five Years Jan 11
Alnylam Pharmaceuticals, Inc. Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy Jan 08
Alnylam Announces Management Appointments Dec 23 Aktionärsrenditen A1LN34 BR Biotechs BR Markt 7D 12.6% -1.5% 2.4% 1Y 119.9% -3.5% -3.2%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: A1LN34 übertraf die Branche BR Biotechs , die im vergangenen Jahr eine Rendite von -3.5 erzielte.
Rendite vs. Markt: A1LN34 übertraf den Markt BR, der im vergangenen Jahr eine Rendite von -3.2 erzielte.
Preisvolatilität Is A1LN34's price volatile compared to industry and market? A1LN34 volatility A1LN34 Average Weekly Movement n/a Biotechs Industry Average Movement 8.7% Market Average Movement 5.1% 10% most volatile stocks in BR Market 9.1% 10% least volatile stocks in BR Market 2.8%
Stabiler Aktienkurs: Es sind keine Daten verfügbar.
Volatilität im Zeitverlauf: Unzureichende Daten , um die Volatilitätsveränderung von A1LN34 im vergangenen Jahr zu bestimmen.
Über das Unternehmen Alnylam Pharmaceuticals, Inc. erforscht, entwickelt und vermarktet Therapeutika, die auf der Interferenz von Ribonukleinsäuren basieren. Das Unternehmen bietet ONPATTRO und AMVUTTRA für hereditäre Transthyretin-vermittelte Amyloidose, GIVLAARI für akute hepatische Porphyrie, OXLUMO für primäre Hyperoxalurie Typ 1 und Leqvio für Hypercholesterinämie an. Das Unternehmen entwickelt außerdem Vutrisiran, das sich in der klinischen Phase III für Transthyretin-Amyloidose (ATTR) mit Kardiomyopathie befindet, Nucresiran, das sich in der klinischen Phase I für ATTR-Amyloidose befindet, Fitusiran, das sich in der klinischen Phase III für Hämophilie befindet; Cemdisiran, das sich in der Phase III der klinischen Prüfung für Myasthenia Gravis und paroxysmale nächtliche Hämoglobinurie sowie geografische Atrophie befindet, und ALN-6400, das sich in der Phase I der klinischen Prüfung für Blutungsstörungen befindet.
Mehr anzeigen Alnylam Pharmaceuticals, Inc.'s Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von Alnylam Pharmaceuticals im Vergleich zum Marktanteil des Unternehmens? A1LN34 grundlegende Statistiken Marktanteil R$209.62b Gewinn(TTM ) -R$1.59b Umsatz(TTM ) R$12.85b
16.3x Kurs-Umsatz-Verhältnis
-131.9x Kurs-Gewinn-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) A1LN34 Gewinn- und Verlustrechnung (TTM ) Einnahmen US$2.25b Kosten der Einnahmen US$323.37m Bruttogewinn US$1.92b Sonstige Ausgaben US$2.20b Umsatz -US$278.16m
Zuletzt gemeldete Gewinne
Dec 31, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) -2.15 Bruttomarge 85.62% Nettogewinnspanne -12.37% Schulden/Eigenkapital-Verhältnis 3,684.7%
Wie hat sich A1LN34 auf lange Sicht entwickelt?
Historische Performance und Vergleiche
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/03/24 05:26 Aktienkurs zum Tagesende 2025/03/21 00:00 Gewinne 2024/12/31 Jährliche Einnahmen 2024/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr .
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github .
Analysten-Quellen Alnylam Pharmaceuticals, Inc. wird von 60 Analysten beobachtet. 30 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Ishan Majumdar Baptista Research Huidong Wang Barclays Emily Bodnar Berenberg
57 weitere Analysten anzeigen 
